HUTCHISON CHINA MED. Stock London S.E.
Stocks
Pharmaceuticals
OTC Markets Traded| Market Cap | 2.02B 1.77B 1.63B 1.5B 2.84B 195B 2.9B 19.51B 7.67B 95.47B 7.6B 7.43B 329B | P/E 2026 * |
38.1x | P/E 2027 * | 36x |
|---|---|---|---|---|---|
| Enterprise Value | 1.32B 1.16B 1.07B 983M 1.85B 127B 1.89B 12.75B 5.01B 62.37B 4.97B 4.86B 215B | EV / Sales 2026 * |
2.09x | EV / Sales 2027 * | 1.87x |
| Free-Float |
61.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HUTCHISON CHINA MED.
| 1 day | -2.79% |
| Manager | Title | Age | Since |
|---|---|---|---|
Chig Fung Cheng
CEO | Chief Executive Officer | 59 | 2025-08-24 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 61 | 2021-12-31 |
Karen Atkin
COO | Chief Operating Officer | 60 | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Edith Shih
BRD | Director/Board Member | 74 | 2005-12-31 |
Chig Fung Cheng
BRD | Director/Board Member | 59 | 2010-12-31 |
Wei Guo Su
BRD | Director/Board Member | 68 | 2017-03-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.79% | -0.24% | - | - | 2.02B | |
| +0.85% | -0.80% | +52.79% | +161.33% | 1,051B | |
| +1.23% | -1.53% | +54.58% | +59.08% | 609B | |
| +0.04% | +2.58% | +34.47% | +86.33% | 450B | |
| +0.78% | -0.71% | +29.28% | +24.10% | 330B | |
| +1.41% | +0.58% | +35.44% | +40.67% | 284B | |
| -0.27% | -1.87% | +22.34% | +22.51% | 263B | |
| -1.76% | +2.37% | -20.43% | -38.00% | 223B | |
| -1.42% | +0.80% | +24.27% | +57.50% | 198B | |
| -1.48% | +3.43% | +24.08% | +71.67% | 167B | |
| Average | -0.34% | +0.54% | +28.54% | +53.91% | 397.23B | |
| Weighted average by Cap. | +0.37% | +0.02% | +37.51% | +79.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 634M 554M 511M 471M 888M 61.07B 908M 6.11B 2.4B 29.91B 2.38B 2.33B 103B | 729M 637M 588M 542M 1.02B 70.18B 1.04B 7.02B 2.76B 34.37B 2.74B 2.68B 118B |
| Net income | 44.33M 38.74M 35.75M 32.95M 62.1M 4.27B 63.48M 427M 168M 2.09B 166M 163M 7.2B | 65.3M 57.07M 52.66M 48.54M 91.49M 6.29B 93.52M 629M 248M 3.08B 245M 240M 10.6B |
| Net Debt | -702M -613M -566M -522M -983M -67.59B -1.01B -6.76B -2.66B -33.1B -2.64B -2.58B -114B | -660M -577M -532M -490M -924M -63.54B -945M -6.36B -2.5B -31.12B -2.48B -2.42B -107B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
